StockData

Yarrow Bioscience, Inc. (YARW) stock

YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30102% above fair value
$14.21+0.28 (+2.01%)

Close on Nov 17, 2026Market cap $37.94MP/E –Yield –

Yarrow Bioscience ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Yarrow Bioscience's ebitda for the twelve months ending Jun 30, 2024 was -$30.84M. For fiscal 2025 it was -$29.73M. The highest annual figure on record is -$29.26M in fiscal 2023.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$29.73M–
FY2024Dec 31, 2024-$43.63M–
FY2023Dec 31, 2023-$29.26M–
FY2022Dec 31, 2022-$34.22M–
FY2021Dec 31, 2021-$38.80M–
FY2020Dec 31, 2020-$252.21M–
FY2019Dec 31, 2019-$95.52M–
FY2018Dec 31, 2018-$74.57M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.10M–
Q1 FY2026Mar 31, 2026-$3.81M–
Q2 FY2025Jun 30, 2025-$7.54M–
Q1 FY2025Mar 31, 2025-$9.19M–
Q2 FY2024Jun 30, 2024-$10.40M–
Q1 FY2024Mar 31, 2024-$7.38M–
Q4 FY2023Dec 31, 2023-$6.83M–
Q3 FY2023Sep 30, 2023-$6.23M–
Q2 FY2023Jun 30, 2023-$10.32M–
Q1 FY2023Mar 31, 2023-$5.88M–
Q4 FY2022Dec 31, 2022-$8.14M–
Q3 FY2022Sep 30, 2022-$9.16M–
Q2 FY2022Jun 30, 2022-$8.28M–
Q1 FY2022Mar 31, 2022-$8.65M–
Q4 FY2021Dec 31, 2021-$8.82M–
Q3 FY2021Sep 30, 2021-$10.74M–
Q2 FY2021Jun 30, 2021-$9.51M–
Q1 FY2021Mar 31, 2021-$9.73M–
Q4 FY2020Dec 31, 2020-$21.90M–
Q3 FY2020Sep 30, 2020-$23.42M–
Q2 FY2020Jun 30, 2020-$167.08M–
Q1 FY2020Mar 31, 2020-$39.80M–
Q4 FY2019Dec 31, 2019-$37.34M–
Q3 FY2019Sep 30, 2019-$23.11M–
Q2 FY2019Jun 30, 2019-$19.27M–
Q1 FY2019Mar 31, 2019-$15.81M–

More Yarrow Bioscience figures

See a number that looks wrong?